Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

Urogenital tumors
Urothelial carcinoma of the urinary bladder (incl. renal pelvis, ureter)
Neoadjuvant Therapy
The purpose of the study in Part 1 (dose escalation) and in Part 2 (dose expansion) is todetermine the recommended Phase 2 dose(s) (RP2D[s]) and evaluate preliminary clinicalefficacy. Part 3 (dose expansion) will confirm safety and preliminary clinical activityat the RP2D. Part 4 (RP2D expansion) will assess the overall complete response (CR) inparticipants with intermediate-risk-non-muscle invasive bladder cancer (IR-NMIBC; meansthe cancer cells are only in the bladder's inner lining).
The study is for patients with localized urothelial carcinoma of the bladder. A pretzel with erdafitinib (TAR-210) is to be inserted into the bladder in order to obtain this.